Botulinum Toxin Enhanced Foker Process for Long Gap Esophageal Atresia
Topic overview
Novel surgical approach combines botulinum toxin A with the established Foker traction technique to treat long gap esophageal atresia in neonates. BTX's anti-fibrotic and muscle-relaxing properties may accelerate esophageal growth, potentially reducing operative stages and improving outcomes in this challenging congenital condition.
Key takeaways
- Foker process uses progressive tension to induce esophageal growth in long gap esophageal atresia (LGEA).
- Botulinum Toxin A (BTX) has anti-fibrotic and muscle-relaxing properties relevant to esophageal tissue manipulation.
- BTX may enhance traction-induced esophageal growth when combined with the Foker technique.
- Novel approach targets both mechanical tension and tissue properties to improve LGEA surgical outcomes.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Botulinum Toxin Enhanced Foker Process for Long Gap Esophageal Atresia. GlobalCastMD Medical Library. 2024-07-16. https://dev.library.globalcastmd.com/article/8871?via_space=staycurrentmd
Comments